LAC Med Berhad Q1 2026 Financial Results: Revenue, Profit, Outlook & Segment Analysis

LAC Med Berhad Reports Robust First Quarter 2026 Results, Declares Dividend, and Maintains Strong Order Book

KUALA LUMPUR, 30 May 2026 – LAC Med Berhad (“LAC Med” or “the Group”), a prominent healthcare technology solutions provider, has announced its unaudited consolidated results for the first quarter ended 31 March 2026. The Group delivered a solid financial performance, underpinned by resilient demand across its medical device and healthcare solutions portfolio, and provided an optimistic outlook for the remainder of the year.

Key Financial Highlights

Revenue: RM29.4 million for the quarter, driven by diversified streams including supply of medical equipment (RM11.4 million), related products and services (RM7.2 million), and supply/integration of medical devices (RM10.8 million).
Profit Before Tax (PBT): RM1.7 million, reflecting a strong operational performance.
Gross Profit Margin: 24%, in line with the Group’s historical average. Margin strength was supported by increasing contributions from service and consumables revenue streams, which made up 24% of total revenue this quarter.
Net Profit After Tax: RM1.0 million attributable to both owners and non-controlling interests.
Basic and Diluted Earnings per Share (EPS): 0.26 sen, based on 400 million shares outstanding.
Cash and Cash Equivalents: RM62.2 million at period end, ensuring ample liquidity.

Operational & Segmental Performance

Supply and Integration of Medical Devices: RM10.7 million revenue, recognised over time.
Supply of Medical Equipment: RM11.4 million revenue, recognised at a point in time.
Related Products and Services: RM7.2 million revenue from both over time and point-in-time recognition.

The Group maintains a broad product base, supported by relationships with 11 global medical brands and over 1,200 active SKUs, positioning it as a key multi-solutions partner to hospitals and healthcare providers.

Strategic Developments and Outlook

Dividend Declared: The Board announced a final dividend of 0.65 sen per ordinary share for FY2025, payable on 15 June 2026. This rewards shareholders and reflects management’s confidence in the Group’s cash flow and future prospects.
Order Book and Tender Pipeline: As of 30 April 2026, the order book reached RM199.0 million, providing strong earnings visibility. The Group’s tender book stands at RM690.9 million, indicating continued participation in healthcare infrastructure and technology upgrade projects.
Regional Expansion: PT Fairmed Imaging Nusajaya, LAC Med’s Indonesian subsidiary, is expanding its service presence and market penetration, focusing on recurring and service-oriented revenues, especially for Alpinion products.
Capital Commitments: The Group has significant capital expenditure plans, with RM4.0 million approved (not contracted) and RM14.0 million approved and contracted, aimed at expanding infrastructure and establishing new business lines such as Equipment-as-a-Service (EaaS) and Medical Equipment Asset Management Solutions (MEAMS).
Proceeds Utilisation: From the recent public issue (RM55.6 million raised), RM16.0 million has been used to repay bank borrowings, RM2.4 million for working capital, and RM5.3 million for listing expenses. The remainder will fund new head office/warehouse, Indonesian expansion, and digital solutions.

Financial Position and Risk Factors

Total Assets: RM215.2 million, with significant current assets (RM198.0 million) ensuring liquidity.
Borrowings: RM30.5 million (all secured and RM-denominated), with a notable increase in hire purchase financing to support business expansion.
Effective Tax Rate: 39.8%, exceeding the statutory rate due to non-deductible losses in the Indonesian subsidiary under the country’s final tax regime.
No Material Litigation or Contingent Liabilities: The Group is not subject to any material legal or contingent claims.

Important Shareholder Information & Price-Sensitive Issues

Dividend Payment: The announced dividend is a key development for income-focused investors and signals ongoing profitability and cash generation.
Strong Order and Tender Books: The robust pipeline provides strong earnings visibility and underpins management’s positive outlook, potentially supporting share price appreciation if delivered.
Growth Initiatives: Continued expansion in Indonesia and new digital solution offerings (EaaS, MEAMS) could unlock higher-margin, recurring revenue streams, supporting long-term value creation.
Elevated Effective Tax Rate: Investors should monitor the Group’s tax management, particularly in overseas operations where local tax regimes affect overall profitability.
Rising Administrative Expenses: Primarily due to staff cost increases, reflecting scaling-up of operations but potentially impacting near-term margins if not matched by higher revenue growth.
Geopolitical & Supply Chain Risks: The Group remains vigilant over global logistics and freight cost uncertainties, although impact is currently deemed manageable.

Management Outlook

Management remains cautiously optimistic, citing favourable macro trends in Malaysian and regional healthcare: rising healthcare investment, digitalisation, ageing demographics, and increasing prevalence of chronic diseases. The Board is confident that its diversified, service-oriented model will ensure sustainable earnings growth, margin resilience, and long-term shareholder value. Barring unforeseen circumstances, LAC Med expects to maintain its growth trajectory for the financial year ending 31 December 2026.

Disclaimer

This article is prepared for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisers before making investment decisions.

LAC Med Berhad Umum Keputusan Suku Pertama 2026 yang Kukuh, Isytihar Dividen & Kekalkan Buku Pesanan Kukuh

KUALA LUMPUR, 30 Mei 2026 – LAC Med Berhad (“LAC Med” atau “Kumpulan”), penyedia penyelesaian teknologi penjagaan kesihatan terkemuka, telah mengumumkan keputusan konsolidasi tidak diaudit untuk suku pertama berakhir 31 Mac 2026. Kumpulan menunjukkan prestasi kewangan yang kukuh, didorong oleh permintaan berterusan terhadap portfolio peranti perubatan dan penyelesaian penjagaan kesihatan mereka, serta memberikan prospek optimis untuk baki tahun ini.

Sorotan Kewangan Utama

Hasil: RM29.4 juta untuk suku tersebut, dipacu oleh bekalan peralatan perubatan (RM11.4 juta), produk & perkhidmatan berkaitan (RM7.2 juta), dan bekalan/integrasi peranti perubatan (RM10.8 juta).
Untung Sebelum Cukai (PBT): RM1.7 juta, mencerminkan prestasi operasi yang mantap.
Margin Untung Kasar: 24%, sejajar dengan purata sejarah Kumpulan. Sumbangan daripada hasil perkhidmatan dan barangan guna habis menyokong margin ini, merangkumi 24% dari hasil keseluruhan suku ini.
Untung Bersih Selepas Cukai: RM1.0 juta bagi pemilik dan kepentingan bukan kawalan.
Pendapatan Asas & Dicairkan Sesaham (EPS): 0.26 sen, berdasarkan 400 juta saham diterbitkan.
Tunai & Setara Tunai: RM62.2 juta pada akhir tempoh, memastikan kecairan yang kukuh.

Prestasi Operasi & Segmen

Bekalan & Integrasi Peranti Perubatan: RM10.7 juta hasil, diiktiraf secara berperingkat.
Bekalan Peralatan Perubatan: RM11.4 juta hasil, diiktiraf sekali gus.
Produk & Perkhidmatan Berkaitan: RM7.2 juta hasil dari pengiktirafan secara berperingkat dan sekali gus.

Kumpulan mengekalkan asas produk yang luas, disokong oleh kerjasama dengan 11 jenama perubatan global dan lebih 1,200 SKU aktif, memposisikan mereka sebagai rakan kongsi multi-penyelesaian kepada hospital dan penyedia penjagaan kesihatan.

Perkembangan Strategik & Prospek

Dividen Diisytihar: Lembaga mengumumkan dividen akhir 0.65 sen sesaham bagi tahun kewangan 2025, dibayar 15 Jun 2026. Ini menguntungkan pelabur dan mencerminkan keyakinan pengurusan terhadap aliran tunai dan prospek masa depan.
Buku Pesanan & Tender Kukuh: Sehingga 30 April 2026, buku pesanan mencecah RM199.0 juta, memberi kejelasan pendapatan kukuh. Buku tender pula RM690.9 juta, menunjukkan penyertaan berterusan dalam projek infrastruktur dan teknologi penjagaan kesihatan.
Pembangunan Serantau: PT Fairmed Imaging Nusajaya di Indonesia memperluas liputan perkhidmatan dan penembusan pasaran, fokus pada hasil berulang dan berorientasikan perkhidmatan, khususnya produk Alpinion.
Komitmen Modal: Kumpulan mempunyai rancangan perbelanjaan modal yang signifikan, RM4.0 juta telah diluluskan (belum dikontrak) dan RM14.0 juta telah diluluskan & dikontrak, untuk memperluas infrastruktur dan mewujudkan perniagaan baharu seperti EaaS & MEAMS.
Penggunaan Hasil Terbitan Saham: Daripada terbitan awam baru-baru ini (RM55.6 juta), RM16.0 juta digunakan untuk bayar balik pinjaman, RM2.4 juta untuk modal kerja, dan RM5.3 juta untuk perbelanjaan penyenaraian. Baki untuk pembukaan ibu pejabat/gudang baharu, pengembangan di Indonesia, dan penyelesaian digital.

Kedudukan Kewangan & Faktor Risiko

Jumlah Aset: RM215.2 juta, dengan aset semasa signifikan (RM198.0 juta) memastikan kecairan.
Pinjaman: RM30.5 juta (semua bercagar & denominasi RM), dengan peningkatan ketara dalam pembiayaan sewa beli untuk menyokong pengembangan perniagaan.
Kadar Cukai Efektif: 39.8%, melebihi kadar statutori akibat kerugian tidak boleh ditolak di anak syarikat Indonesia di bawah rejim cukai akhir negara itu.
Tiada Litigasi atau Liabiliti Kontinjen Material: Kumpulan tidak tertakluk pada tuntutan undang-undang atau kontinjen yang material.

Maklumat Penting untuk Pemegang Saham & Isu Sensitif Harga

Pembayaran Dividen: Pengumuman dividen adalah berita penting bagi pelabur yang mencari pendapatan dan menandakan keuntungan serta penjanaan tunai berterusan.
Buku Pesanan & Tender Kukuh: Saluran pendapatan yang kukuh menyokong prospek positif pengurusan dan boleh memacu harga saham jika dapat direalisasikan.
Inisiatif Pertumbuhan: Pengembangan berterusan di Indonesia dan tawaran penyelesaian digital baharu (EaaS, MEAMS) boleh membuka hasil berulang margin tinggi untuk jangka panjang.
Kadar Cukai Efektif Tinggi: Pelabur harus memantau pengurusan cukai Kumpulan, khususnya operasi luar negara yang memberi kesan kepada keuntungan keseluruhan.
Peningkatan Perbelanjaan Pentadbiran: Terutama akibat peningkatan kos kakitangan, mencerminkan pengembangan operasi tetapi boleh menekan margin jika tidak diimbangi pertumbuhan hasil.
Risiko Geopolitik & Rantaian Bekalan: Kumpulan kekal berwaspada terhadap ketidaktentuan logistik global dan kos pengangkutan, walaupun kesan kini masih terkawal.

Prospek Pengurusan

Pihak pengurusan kekal optimis, memetik trend makro positif dalam penjagaan kesihatan Malaysia dan serantau: pelaburan penjagaan kesihatan yang meningkat, pendigitalan, demografi menua, dan peningkatan penyakit kronik. Lembaga yakin model perkhidmatan dan hasil berulang akan memastikan pertumbuhan keuntungan mampan, daya tahan margin, dan nilai pemegang saham jangka panjang. Melainkan perkara luar jangka, LAC Med menjangka untuk mengekalkan momentum pertumbuhannya bagi tahun kewangan berakhir 31 Disember 2026.

Penafian

Artikel ini disediakan untuk tujuan maklumat sahaja dan tidak merupakan nasihat pelaburan atau cadangan untuk membeli atau menjual sekuriti. Pelabur dinasihatkan menjalankan kajian sendiri dan mendapatkan nasihat profesional sebelum membuat keputusan pelaburan.